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vided 0.30 and Docetaxel 0.31. Therefore, Erlotinib therapy is positioned as a dom-
inant (more effective and less costly) compared to Docetaxel and Pemetrexed.
These results were consistent in the sensitivity analysis, giving strength to them.
Therefore, Erlotinib could represent annual savings of $5860 compared to Do-
cetaxel and $7090 with Pemetrexed per patient. Additionally, Erlotinib contributes
to costs reduction in patients with NSCLC, because it is a chemotherpay adminis-
tered orally, instead os a intravenous infusion, andwith a better safety profilewithno
hematologic toxicity in comparison with standard chemotherapy. CONCLUSIONS:
The cost-utility analysis of the use of Erlotinib vs. Docetaxel or Pemetrexed in the
treatment of previously treated metastatic or advanced NSCLC showed that Erlo-
tinib is a cost-effective therapy because it consumes fewer resources to obtain
clinical success. Under the perspective of the Mexican public health system Erlo-
tinib is dominant alternative in second-line treatment for patients with advanced
or metastatic NSCLC.
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OBJECTIVES: Cancer is the second leading cause of death in the Slovak Republic
with 23 000 new cases diagnosed every year and highest incidence in age group
over 60. Antineoplastic agents prevent or inhibit the maturation and proliferation
of neoplasms. Themain objective of this studywas to evaluate the consumption of
antineoplastic agents in Slovak Republic within the period of 2008-2011.
METHODS: Analysed data were abstracted from the Slovak Institute of Drug Con-
trol and provided by wholesalers due to their legal obligation towards the SIDC.
Processed informations include the number of medicine packages and financial
expenditures. RESULTS: There was a gradual rise in antineoplastic agents utilisa-
tion in terms of financial expenditures from 98 605 418 € in 2009 to 105 786 256 € in
2011. Third quartal of 2010 was hitting a peak with 27 261 629 € respectively while
the first quartal plummeted to 23 307 249 €, which presents the lowest performance
within followed period. Number of packages rose sequentially from 513 193 in 2008
to 593 067 in 2011. Average price per package was fluctuating from 168 € in 2010 to
192 € in 2008. Highest financial declinewas observed in group of plant alkaloids and
other natural products ( from 12 977 717 € in 2008 to 6 840 618 € in 2011). Most
significant expeditures increase from the group of antineoplastic agents reached
capecitabinewith 3 491 954 € in 2008 and 4 560 623 € in 2011. Its number of packages
almost doubled from 8 725 in 2008 to 14 145 in 2011. CONCLUSIONS: The slight rise
in consumption of antineoplastic agents is caused by higher incidence and preva-
lence and better diagnose of cancer disease in Slovak population. Higher use of
capecitabine can be interpretted in pursuance of breast and colorectal cancer oc-
curence.
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OBJECTIVES: Innovative pharmaceutical treatments contribute significant value
for improving and extending the lives of cancer patients. Many innovative oncol-
ogy products become standard of care and continue to produce significant value
well beyond the period of innovator exclusivity. Current tools used to guide 3rd
party funding decisions are made at the beginning of product lifecycles and fail to
account for the long-term stream of value, particularly from acquisition cost re-
duction after innovator exclusivity. The objective of this study was to propose a
framework to highlight this important aspect for determining the value of new
drug innovation using two case studies. METHODS: The drugs selected for the
cases studies were paclitaxel and azacitidine. Pharmacoeconomic studies evaluat-
ing these agents were identified. Applying off-patent prices after exclusivity, a
lifecycle ICER was determined by annually amortizing the ICER value over the
potential useful life of a product. Results are in Canadian dollars. RESULTS: Pacli-
taxel remains a standard of care in advanced ovarian and breast cancer even after
innovator loss of exclusivity in 2004. Using the current off-patent price, the lifecycle
ICER for paclitaxel is estimated to be approximately $26,000 per QALY. Azacitidine
has become the standard of care for higher-risk MDS in Canada. It is anticipated
that azacitidine will remain part of standard care beyond innovator exclusivity.
Assuming a 25% reduction in acquisition cost and a further 10 year useful life, the
lifecycle ICER for azacitidine is estimated to be approximately $36,000 per QALY.
CONCLUSIONS: Many innovative oncology medicines provide significant societal
value well past the period of innovator exclusivity. Current approaches for assess-
ing economic value fail to recognize this unique aspect and may be undervaluing
new oncology medicines. Therefore, approaches should evolve to better account
for the societal value a product produces over its useful life span.
CANCER – Patient-Reported Outcomes & Patient Preference Studies
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OBJECTIVES: Identify explanatory variables of hormone therapy (HT) adherence
and persistence (A&P) in women with breast cancer (BC), and evaluating the effect
of such variables in BC survival rates. METHODS: Retrospective longitudinal data
from a cohort of 5861 women with BC, submitted to HT, was put together through
linkage of the Brazilian National Cancer Institute datasets, including the control of
medicines delivered at its Pharmacy. A logistic regression model was applied to
study adherence. Cox proportional hazard models were used to estimate persis-
tence and BC survival. RESULTS: The proportion of treatment adherent was 75.3%.
At the end of the first and the fifth year of treatment, respectively, overall persis-
tence to treatment was 79% and 31%, and survival was 94% and 71%. Similarly,
better A&P to treatment, as well as BC survival, were associated with higher edu-
cation, having a partner, lower cancer stages, being submitted to surgery, having
less inpatient care, making outpatient visits to a Mastologist and a Clinical Oncol-
ogist, and the need of less exams. Older women were more likely to adhere and to
persist to treatment, but those aged 70 years old or more presented higher hazard
of death. Alcoholism and tobacco use was associated with lower A&P. Longer time
between diagnosis and the beginning of HT and cancer family historywere, respec-
tively, a risk and a protective factor to treatment persistence and survival. Psycho-
therapy was protective for adherence and survival. Finally, treatment adherence
was positively associated with BC survival, being combined tamoxifen and aroma-
tase inhibitor explicative of lower adherence, while only aromatase inhibitor use
was associated with higher hazard of death. CONCLUSIONS: In this cohort, of
the patients did not adhere, only 31% completed the 5-year hormone treatment,
and 71% were alive after five years. Socio-demographic, behavioral, clinical and
health care aspects explained partially variations in these dependent variables.
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HOW REMAINING YEARS OF LIFE ARE TRADED? – A FEASIBILITY STUDY TO
EXPLORE THE APPLICABLENESS OF TIME-TRADE-OFF METHOD IN CHRONIC
MYELOID LEUKEMIA OUTPATIENTS TREATED WITH IMATINAB IN TAIWAN
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OBJECTIVES: Since the launch of Imatinib, the survival of chronic myeloid leuke-
mia (CML) has significantly improved, but also caused enormous increase in long-
termcosts of CML care. Neither health-related utility of CMLpatients nor long-term
cost-effectiveness of imatinib, however, has been investigated in Taiwan. This
feasibility study aims to explore the applicableness of time-trade-off (TTO) tomea-
sure utility of CML patients treated with imatinib.METHODS: This cross-sectional
study was conducted at a medical center in southern Taiwan from June 2011 to
January 2012. Outpatients with defined diagnosis of CML and receiving imatinib
were invited to participate. After TTO measurement, semi-structure interviews
were conducted to explore participates’ perceptions. The interviews were audio-
taped, transcribed verbatim and analyzed by constant comparison untill
saturation. RESULTS: Of all, 22 (mean age: 52.415.83 years, male: 63.6%) of the 24
participants completed the study. The average utility was 0.7740.219. Most par-
ticipants accepted current health status and life expectancy, and considered cur-
rent health status is not different from ideal situation. Mid-age participants traded
off life span with parenting duty, while the elderly considered companion time
with their partners. For those who chose shorter life span with better health, the
main concern was financial burden to family because the disease-related fatigue
constrained activity and work ability. In addition, regular medical treatment was
also considered by those who desired better career paths, long-term traveling and
those consisting ofmulti-comorbidity. Moreover, uncertainty about future, limited
social support and financial difficulty were also the reasons for trading off.
CONCLUSIONS: TTO is applicable to measure utility for CML patients. Participants
receiving imatinib generally presented satisfactory health status and trading re-
maining years of lifewith other concerns. To validate this tool, further studies need
to explore utilities of patients with disease symptoms or drug-related side effects,
and compare the results with disease-specific measures.
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OBJECTIVES: The limitations of generic preference-based measures in disease ar-
eas such as oncology are widely recognised. Condition-specific measures offer
more relevant assessments of health and can be used to derive utilities. The aim of
this study was to use data collected with the European Organization for Research
and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer (QLQ-
C30) in a myelofibrosis clinical trial to derive utilities. METHODS: QLQ-C30 data
were collected over 48 weeks in an open-label trial of ruxolitinib (n146) versus
best-available therapy (BAT) (n73). Two algorithms were used to map QLQ-C30
scores to utilities: the first mapped to EQ-5D utilities, the second to condition-
specific preference weights using a QLQ-C30 item subset (EORTC-8D). Changes
from baseline (CFB) in utilities were calculated by treatment at week 48. Mean
utilities by presence of constitutional symptoms (CS) (weight loss, fever or night
sweats) and response (35% reduction in spleen volume from baseline) were also
derived. RESULTS:Mean (SE) utility CFB from the EQ-5D algorithmwas 0.082 (0.025)
for ruxolitinib and 0.012 (0.040) for BAT. From the EORTC-8D algorithm, mean (SE)
CFB was 0.038 (0.013) for ruxolitinib and 0.013 (0.021) for BAT. Patients without CS
had highermean (SE) utilities than patientswith CS using both algorithms—EQ-5D,
0.730 (0.017) without and 0.539 (0.031) with CS; EORTC-8D, 0.818 (0.009) without and
0.719 (0.016) with CS. Similarly, patients defined as responders had higher mean
(SE) utilities than nonresponders using both algorithms—EQ-5D, 0.754 (0.029) for
responders and 0.670 (0.024) for nonresponders; EORTC-8D, 0.843 (0.015) for re-
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sponders and 0.785 (0.012) for nonresponders. CONCLUSIONS:Utility values can be
derived from condition-specificmeasures such as the QLQ-C30. Our analyses dem-
onstrate that the presence of CS and splenomegaly in patients with myelofibrosis
results in lower utility values.
PCN96
A SYSTEMATIC REVIEW OF HEALTH STATE UTILITIES IN PATIENTS WITH
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OBJECTIVES: To examine published evidence describing preference-based utility
weights for hepatocellular carcinoma (HCC) in order to inform health gains within
future economic evaluations in HCC.METHODS: The systematic review of utilities
reported in the technology appraisal submission to the National Institute for
Health and Clinical Excellence for sorafenib for advanced HCC (TA189) was up-
dated. Studies that reported preference-based utility weights for HCC indexed in
the EMBASE.comdatabasewere searched for and included. Bibliographic searching
of included studies was conducted to retrieve any additional, relevant studies.
Health technology assessments (HTA) submissions reporting relevant data were
also included. RESULTS: Forty-eight published studies (with 13 primary studies
reporting unique data) and two HTA submissions met the inclusion criteria. Four
studies directly measured utility or quality of life (QoL) used to derive utility values
of patients with HCC; instruments such as the EQ-5D and/or Health Utilities Index
Mark Three, or free-standing techniques such as standard gamble or time trade-off
(TTO) were employed. The two HTA submissions reported utility weights associ-
ated with HCC derived by mapping FACT-HEP clinical trial data to TTO utility
values. One cross-study comparison of estimates highlighted that patientswithout
the disease consider the utility associated with HCC to be lower (0.2-0.5) than
patients with HCC (0.6-0.8). Utility weights were broadly similar across studies
which directlymeasured utility frompatients with HCC orwhichmappedQoL data
from patients with HCC to utility weights, despite differences in study country and
utility instrument. Four studies measured QoL using the SF-36 or FACT-G; all dem-
onstrated that scoreswere lower for the general health perception domain than the
other domains. CONCLUSIONS: Consistent with trends documented elsewhere in
the literature, utility weights derived from patients with disease were generally
higher than those derived from individuals without. There exists little variation in
utility score by instrument applied.
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OBJECTIVES: Preference-based scoring approaches to measuring health-related
quality of life (HRQL) in cancer are proliferating. The objective of this study was to
compare preference-based scores estimated by scoring functions for the generic
EQ-5D and cancer-specific Functional Assessment of Cancer Therapy (FACT) in
terms of differences between algorithms and cancer subtype.METHODS: Second-
ary data analysis of patients with advanced cancer (breast, brain, colorectum,
hepatobiliary system, lung, and ovary; n41 to 49 for each subgroup) was con-
ducted. Each patient completed both the EQ-5D and FACT; scores were calculated
using scoring functions for EQ-5D (Dolan, Shaw et al), an EQ-5D mapping function
(Cheng et al) and FACT (Kind/Macran, Dobrez et al). ECOG performance status rated
by physician was used to stratify patients by severity. The relative statistical effi-
ciency (RE) of each algorithm to capture differences in severitywas compared using
ratios of F-statistics. RESULTS: The rank order of the scores generated by different
scoring functions were fairly consistent across cancer subtype, with the lowest
mean scores derived from FACT by Kind/Macran (0.52, hepatobiliary, to 0.57, colo-
rectal), and highest mean scores using scoring by Dobrez et al (0.80, hepatobiliary,
to 0.85, brain). Within each scoring function, no statistically significant differences
in mean scores were found across cancer types. The Dolan algorithm resulted in
largest differences inmean scores by severity (ECOG) grades for brain, breast, colo-
rectal and ovarian cancer. The FACT UK societal algorithm by Kind et al had the
largest RE for 3 of the cancers (breast, hepatobiliary, and ovarian cancer).
CONCLUSIONS: Each scoring approach produced different preference-based
scores within and across subtype of cancer; extrapolating from ability to discrim-
inate levels of severity EQ-5D scoring functions generally provided scores that
would extrapolate to larger QALY benefits compared to FACT-based approaches.
No statistically significant differences in the utility scoreswere observed across the
cancer types, but some differences could be considered meaningful; lack of power
was a limitation.
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OBJECTIVES: Preference-based measures have been derived from various descrip-
tive HRQOLmeasures. A general 2-stagemethod has evolved: 1) an item from each
domain of the HRQOL measure is selected to form a health state classification
system (HSCS), and 2) a sample of health states is valued and an algorithm derived
for estimating the utility of all possible health states. The outputs of these two
stages represent a MAUI. Our aim was to adapt the first stage for the widely-used
cancer-specific QLQ-C30, and apply it to a large, heterogeneous, international da-
taset as the first step in developing an internationally-valid cancer-specific MAUI.
METHODS: Secondary analyses were conducted on a pooled dataset comprising
QLQ-C30 responses plus demographic and clinical data from 2616 patients from
eight countries, over 14 cancer sites, all stages, and all common cancer treatments.
The established domain structure of the QLQ-C30 (physical, role, emotional, social
and cognitive functioning, plus several symptoms) formed the underlying concep-
tual model for the MAUI. Generalisability of the conceptual model across cancer
sites was tested with multi-group CFA. Items within each domain were then sub-
jected to statistical scrutiny, including Rasch analysis for domains with sufficient
items. RESULTS: CFA results supported the proposed conceptual model and its
generalisability across cancer sites. Two items exhibited floor effects (75% obser-
vations at lowest score), none exhibited misfit to the Rasch model, one exhibited
disordered item response thresholds, and two exhibited differential item function
by cancer site. These results, along with results for responsiveness and qualitative
patient input (analyses underway) will be presented. CONCLUSIONS: The next
stage of this research will obtain valuations for a range of health states defined by
the HSCS from general population samples in various countries. The ability to
determine a preference-based utility score from QLQ-C30 responses will facilitate
cost-utility analysis in cancer trials which use the QLQ-C30.
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OBJECTIVES: Although less than 5% of breast cancers occur among women under
45, the impact on health-related quality of life (HRQOL) may be significant since
these cancers strike earlier in a woman’s life. This study addresses a gap in the
literature on the health utility impacts of breast cancer among U.S. women ages
18-44. METHODS: Self-reported cancer history and HRQOL for US women were
measured from the 2009 and 2010 Behavioral Risk Factor Surveillance System
(BRFSS), a nationally representative population-based survey. BRFSS did not in-
clude preference-based measures of HRQOL, so Jia et al.’s (2011) mapping of
HealthyDays (HRQOL-4) to the EQ-5D and Shawet al.’s (2005) estimates of US utility
weights were applied. The difference in health utilities and in Healthy Days (non-
preference-weighted) was assessed using multivariate regression controlling for
sociodemographics and major health risk factors. RESULTS: A total of 343 of
133,294 women ages 18-44 in the 2009-2010 BRFSS reported breast cancer. Unad-
justed mean utility was .073 lower (p0.01) among women with a history of breast
cancer. Among women ages 45 and older, the difference was much smaller, 0.008
(p0.01). Adjusting for sociodemographic factors and years since diagnosis, the
decrease in health utility for breast cancer was 0.090 lower (p0.01) for women
18-44; similar analysis of women ages 45 and older with breast cancer showed an
estimated impact of 0.017 (p0.01). Mean unhealthy days (physical, mental, or
activity limitations) were also significantly lower in younger women with breast
cancer. CONCLUSIONS: Although women 18-44 are a small fraction of breast can-
cer cases, the health utility impact at the individual level is substantial. Although
the utility decrement is significant for women of all ages, the impact of breast
cancer is 5-6 times greater in younger women. Age-specific utility values of breast
cancer are critical for generating accurate results from cost-utility and modeling.
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WOMEN’ PREFERENCES FOR CHEMOTHERAPY IN THE TREATMENT OF EARLY
STAGE BREAST CANCER
Tang CH, Hung YW, Sung CY, Chuang PY, Chen TF
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OBJECTIVES: Patient choice is increasingly recognized as a key factor in medical
decision making process. This study aims to investigate preferences for adjuvant
chemotherapy among women with early stage breast cancer in Taiwan.
METHODS: Patient interviews were administered on women aged under 60 who
sought treatment for stage I or II stage breast cancer at the outpatient department
of two medical centers located in Taipei City, Taiwan. Five attributes of adjuvant
chemotherapy was identified as the key determinants when making choices: fre-
quency and administraton, length of treatment, cardiac toxicity, recurrence rate,
and out-of-pocket payments.Survey questionnaire was designed based upon dis-
crete choice experiments (DCEs). Preferences for 13 choice sets were elicited with
opt-out option included. In total, 104 respondents were recruited by the end of
2011. Multinomial logit model was used to assess the relative value of product
features and trade-off between attributes. Cluster analysis was used to Isolate
women groups who place differing importance on different features. RESULTS:
Descriptive statistics showed that most women were marred (77.2%) with mean
age of 48.0. About half of the women were ful-time employed (52.6%) and 35.1 of
them received years of education  16 years (35.1%). Prelimanary regression anal-
ysis indicated that women significantly preferred shorter length of treatment, no
cardiac toxicity, lower recurrence rate and lower out-of-pocket payment.
CONCLUSIONS: The authorities concerned should incorporate patients’ prefer-
ences into the existing decision making process when making reimbursement
decision.
A225V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
